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I n t r o d u c t i o n. Ovarian cancer is the fourth most common gynecological malignancy in Poland (after breasr cancer,
lung cancer and cercical cancer) and the second leading cause of death from gynecological malignancy (after cervical cacer).
An objective response to cytotoxic chemotherapy occurs in the majority of individuals with cancers of the ovary.
M a t e r i a l  a n d  m e t h o d s. 54 patients (of 215), who were treated in our clinic between January 2000 and March 2001 we-
re included in the study. Eligibility criteria were: 1) histologically confirmed diagnosis of advanved ovarian cancer, 2) prima-
ry cytoreductive surgery, 3) Karnofsky performance status 70% and cognitive abilities allowing for filling in the questionnaire.
Quality of life was measured using EORTC-C30 (version 3.0) questionnaire.
Re s u l t s. Higher score of nausea and vomiting was observed in the group of patients treated with PC regimen, as compared to
paclitaxel and carboplatin. However, those patients had significantly better social functioning. Cyclophosphamide and cispla-
tin more often caused dyspnoea, sleeping and appetite problems. PC regimen affected cognitive functioning and role functioning
less, as compared to paclitaxel and carboplatin. There was no significant difference in general functioning between the two groups.
C o n c l u s i o n s. Global quality of life in patients treated with paclitaxel/carboplatin was the same as in patients treated with
PC regimen. Higher scores in symptom and single-item scale were observed in patients treated with the PC regimen. Paclita-
xel/carboplatin regimen influenced the quality of life more in the functional scale. In order to obtain objective assessment of
the quality of life larger population study is necessary.
Porównanie jakoÊci ˝ycia chorych z zawansowanym rakiem jajnika
w trakcie chemioterapii z zastosowaniem paklitakselu z karboplatynà
oraz tradycyjnego schematu PC w pierwszej linii leczenia – doniesienie wst´pne
W s t ´ p. W Polsce rak jajnika jest czwartym pod wzgl´dem cz´stoÊci wyst´powania nowotworem u kobiet (po raku piersi, p∏u-
ca i szyjki macicy) i drugà co do cz´stoÊci przyczynà zgonów z powodu nowotworów narzàdów rodnych (po raku szyjki ma-
cicy). Celem naszego badania by∏o porównanie wp∏ywu tradycyjnego schematu PC, zawierajàcego cyklofosfamid i cisplaty-
n´ oraz nowoczesnego leczenia paklitakselem z karboplatynà na jakoÊç ˝ycia pacjentek z zaawansowanym rakiem jajnika.
M a t e r i a ∏  i m e t o d y. JakoÊç ˝ycia mierzona by∏a za pomocà kwestionariusza QLQ-C30 (wersja 3.0), opracowanego przez
EORTC. W badaniu wzi´∏y udzia∏ 54 pacjentki spoÊród 215, z histologicznie potwierdzonym rakiem jajnika, leczone wg sche-
matu PC lub paklitakselem z karboplatynà jako chemioterapia pierwszego rzutu. W grupie chorych leczonych schematem PC,
w porównaniu do paklitakselu z karboplatynà, obserwowano cz´stsze wyst´powanie nudnoÊci i wymiotów, dusznoÊci, zabu-
rzeƒ snu oraz ∏aknienia. Jednak˝e schemat PC w mniejszym stopniu wp∏ywa∏ na spo∏eczny aspekt ˝ycia. ZaobserwowaliÊmy
tak˝e mniejszy wp∏yw schematu PC na funkcje poznawcze i prac´. Nie stwierdziliÊmy natomiast ró˝nic w ogólnej jakoÊci ˝y-
cia chorych leczonych obiema metodami leczenia.
W n i o s k i. Ogólna jakoÊç ˝ycia chorych leczonych z zastosowaniem paklitakselu i karboplatyny jest taka sama, jak chorych
leczonych wed∏ug schematu PC. Zaobserwowano wi´kszy wp∏yw schematu PC na jakoÊç ˝ycia w skali objawowej. Natomiast
paklitaksel z karboplatynà wywiera∏ wi´kszy wp∏yw na jakoÊç ˝ycia w skali funkcjonalnej. W celu obiektywnej oceny wp∏ywu
obu metod leczenia na jakoÊç ˝ycia konieczne jest obj´cie badaniem wi´kszej liczby chorych.
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Introduction
Ovarian cancer is the fourth most common gynecologic
malignancy in Poland (after breast cancer, lung cancer
and cervical cancer) and the second leading cause of de-
ath from gynecological malignancy (after cervical can-
cer) [1]. An objective response to cytotoxic chemotherapy
occurs in a majority of individuals with cancers of the
ovary. Cisplatin-based combiantion chemotherapy allows
a high clinical response rate in ovarian carcinoma. Befo-
re the introduction of paclitaxel, cyclophosphamide and
cisplatin (PC regimen) was the only first line treatment of
advanced ovarian cancer. Adminisrtation of paclitaxel in
combiantion with cisplatin as first line treatment resulted
in longer overall and disease-free survival [2, 3]. It is sug-
gested that cisplatin could be repalced with carboplatin in
order to decrease nephro- and neurotoxity. Several pro-
spective randomized trials comparing cisplatin to carbo-
platin have demonstrated similar efficacy and little ne-
phro- and neurotoxity of carboplatin in combiantion with
paclitaxel [4, 5]. However, carboplatin has been shown
to cause myelosupression [4]. Prolongation of life expec-
tancy and tumor shrinkage have traditionally been taken
as outcome measures when evaluating the efficacy of me-
dical treatment on cancer. Despite the substantial side
effects and functional impairment often associated with
cancer treatment, only recently attention has been given
to the assessment of quality of life [6, 7].
Aim of study objectives
The purpose of our study was to compare the effect of in-
travenous cyclophosphamide/cisplatin and paclitaxel/car-
boplatin as first line chemotherapy in patients with advan-
ced ovarian cancer after primary cytoreductive surgery.
Material and methods
54 patients (of 215), treated in our clinic between January 2000
and March 2001, were included in the study. Eligibility criteria
were: 1) histologically confirmed diagnosis of advanced ovarian
cancer, 2) primary cytoreductive surgery, 3) Karnofsky perfor-
mance status 70% and cognitive abilities allowing for filling in
the questionnaire. 24 patients received the PC regimen (cyclo-
phosphamide 750 mg/m2 and cisplatin 75 mg/m2). The rema-
ining 30 patients were treated with paclitaxel and carboplatin
(paclitaxel 135mg/m2 in 24 hour intravenous infusion and carbo-
platin administration according to the Calvert formula – car-
boplatin (mg)=AUCx (GFR+25)). Quality of life was measured
using EORTC QLQ-C30 (version 3.0) questionnaire. QLQ-C30
has been carefully developed in a multi-cultural setting by the
European Organiztion for Research and Treatment of Cancer in
1986. The instrument has been shown to be valid, reliable and re-
sponsive to change. Disease-specific modules are available to
supplement the core questionnaire. Study results can be compa-
red across trials. The questionnaire can be easily understood
by most patients and is quick to complete (mean time 11 minu-
tes). QLQ-C30 consists of 30 items and a number of scales
(5 functioning scale-physical, role, cognitive, emotional, social;
3 symptom scales – fatigue, pain, nausea/vomiting; 1 global he-
alth status and supplementary modules containing additional
items and scales – constipation, diarrhoea, sleep, dyspnoea, ap-
petite, financial.
A high score for functioning scales and the global scale
indicate a high level of functioning or quality of life. A high sco-
re for a symptom scale or a single-item scale reveal a high level
of symptom or problem (8, 9).
Quality of life questionnaire was handed to patients at
subsequent 3rd or 4th chemotherapy course, after their consent to
participate in the study. Whenever instructions were not under-
stood or questions were confusing additional explanation was gi-
ven. Questions were read out and questionnaire filled in when
a patient was unable to fill in the questionnaire herself.
The analysis comprised age, FIGO stage, economic sta-
tus, education and residual disease after primary cytoreductive
surgery and Ca 125 antigen level. There were no statistically si-
gnificant differences between the two groups apart from age
(p=0.038). In the group of patients treated with paclitaxel and
carboplatin the age was significantly lower comparing to the
group of patients treated with PC regimen.
All scores were obtained from scales and single-item me-
asuring range from 0-100 according to the guidelines provided by
EORTC [10]. Patients characteristics and quality of life scores
were analysed with statistical Mann-Whitney U Test.
Results
Patients characteristics are summarized in Table I. Figures
1 and 2 show quality of life scores in functional, global and
symptom scales. Patients treated with PC regimen presen-
ted higher scores in the functional scale – social functio-
ning. There were no differences between the two groups
in the remaining aspects of the functional scale. Patients
treated with paclitaxel and carboplatin reported fewer
symptom scores in the following items: nausea/vomiting,
sleeping and appetite problems. Global quality of life was
the same in the two groups.
Discussion
Introduction of paclitaxel to the treatment of advanced
ovarian cancer resulted in a better response rate and im-
provement of a progression-free interval. Combination
Figure 1. QoL RESULTS functional scales and global quality of life Figure 2. QoL RESULTS symptom scales and single items
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of paclitaxel and platinum compound has recently become
the new standard of care for advanced ovarian cancer.
The use of paclitaxel and cisplatin, even in therapeutic do-
ses, has been shown to develop dose-limiting general toxi-
city. Both paclitaxel and cisplatin are neuro- and nephro-
toxic agents. For this reason the use carboplaitn (a less to-
xic platinum compound) instead of cisplatin is thought
to be feasible. Current data has shown that paclitaxel in
combination with carboplatin produces an identical re-
sponse rate, progression-free interval and median ove-
rall survival [11]. However, those two agents appear to
cause myelotoxity [11].
It is only recently that attention has been given to the
assessment of quality of life despite the substantial side ef-
fects and functional impairment often associated with
cancer treatment.
In our study we have compared the effect of intrave-
nous cyclophosphamide/cisplatin and paclitaxel/carbo-
platin as first line chemotherapy on physical and psycho-
logical aspects of quality of life in patients with advanced
ovarian cancer. Nausea and vomiting were observed mo-
re frequently in the group of patients treated with the
PC regimen. However, those patients had significantly
better social functioning (p=0.012).
The global quality of life was the same in both gro-
ups.
The interpretation of the results remains essentially
qualitative. Clinical significance is subjective and is a mat-
ter of opinion. The values and opinions of individual pa-
tients will differ, as will the opinions of the treating clini-
cian and those of society in general. Thus, for a quality of
life measurement scale, it is unlikely that a single thre-
shold value will be universally accepted as a cut-off point
that separates clinically important changes from trivial
and unimportant ones. However, many investigators are
finding that, for a variety of scales assessing overall quali-
ty of life and some of its dimensions, changes of between
5% and 10% (5 and 10 points on the 1-100 scales of
QLQ-C30) are noticeable by patients and regarded as
“significant” [12-14]. Osoba et al. asked patients to com-
plete the QLQ-C30 on repeated occasions, and the pa-
tients also related their perception of change since the
previous time they completed the QLQ-C30. Physical,
emotional, social functioning and global quality of life
scales were evaluated [13]. It was found that when the
scale scores changed by 5 to 10 points, patients describe
their condition as “a little” better (or worse). A change of
10 to 20 was described as “a moderate” change. A change
greater than 20 was “very much” better (or worse) [9,
13].
Our results were interpreted according to the outco-
me measurement proposed by Osoba et al. and recom-
mended by EORTC.
Patients treated with the PC regimen, apart from si-
gnificantly more frequent nausea/vomiting and less so-
cial functioning impairment, presented changes in other
aspects of functioning and symptom scale. We observed
that the PC regimen less influenced cognitive and role
functioning (average difference of successively 6 and 7
points in comparison to paclitaxel/carboplatin regimen).
PC caused dyspnoea, sleeping and appetite problems mo-
re often (average differences successively 6, 6 and 13 po-
ints). Our results suggest that the PC regimen affects the
quality of life more. The fact that there was statistically si-
gnificant difference in age between the two groups (me-
dian 63.5 versus 54.0, p=0.038) could have affected our
results. Currant et al. observed that age, apart from gene-
ral health status and psychosocial functioning, appeared
Table I. Patients, characteristics
Characteristics of patients Number of patients
All First line pc First line paclitaxel/carboplatin
Number of patients N 54 24 30
Age mean 55 60 51
(range) (27 – 78) (40 – 78) (27 – 71)
FIGO stage Ic 4 1 3
IIb 6 2 4
IIc 4 3 1
IIIc 35 17 18
IV 4 4 -
CA 125 mean 134.74 98.45 163.76
(u/ml)
Time from diagnosis <30 mths 54 24 30
>30 mths - - -
Education <high school 14 12 2
high school 19 6 13
graduate school 12 2 10
missing 9 4 5
low 9 2 7
Economic status average 33 15 18
high 12 7 5
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to be the most important risk factor of bad general func-
tioning among patients with early diagnosis of breast can-
cer [15].
Despite the fact that there were no significant diffe-
rences in the global quality of life, we cannot definitely say
that our results were not influenced by a limited num-
ber of patients. Thus, in order to obtain objective asses-
sment of quality of life larger population study is necessa-
ry.
Conclusions
Global quality of life of patients treated with paclita-
xel/carboplatin was the same as of patients treated with
the PC regimen. Higher scores in symptom and single-
-item scale were observed in patients treated with PC re-
gimen. Paclitaxel/carboplatin regimen more significantly
influenced the quality of life in functional scale. In or-
der to obtain objective assessment of the quality of life
a larger population study is necessary.
Piotr Mielcarek M.D.
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